A Phase 1/2 interventional study of AMG 531 in Chemotherapy-Induced Thrombocytopenia, Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-20.
Sponsored by Amgen · Phase 1/2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to identify a well-tolerated, effective dose and schedule of AMG 531 for the treatment of Chemotherapy Induced Thrombocytopenia (CIT) in subjects with lymphoma receiving multi-cycle chemotherapy.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
This study's enrollment of 39 is close to the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Browse Hodgkin Disease studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: AMG 531
Planned Cohorts: 1. 100 mcg, 2. 300 mcg, 3. 700 mcg, 4. 1000 mcg; Optional Cohorts: 5. cohort expansion, 6. schedule change, 7. new dose
Change in Platelet Nadir
Change in platelet nadir from the previous qualifying cycle to the first treatment cycle.
Time frame: 32 weeks
Percentage of Subjects Experiencing Grade 3 or 4 Thrombocytopenia
Percentage of subjects experiencing grade 3 and/or 4 thrombocytopenia (\<50 x 10\^9/L, and \<25 x 10\^9/L)
Time frame: 32 weeks
Duration of Grade 3 or 4 Thrombocytopenia
Duration of grade 3 and/or 4 thrombocytopenia (\<50 x 10\^9/L and \<25 x 10\^9/L, respectively)
Time frame: 32 weeks
Percentage of Subjects That Received Platelet Transfusions
Percentage of subjects that received platelet transfusions during the first romiplostim treatment cycle
Time frame: 32 weeks
Participants were enrolled from 15 March 2006 through 28 April 2008
| Milestone | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 700 µg | Romiplostim 1000 µg |
|---|---|---|---|---|
| Started | 8 | 11 | 11 | 9 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 8 | 11 | 11 | 9 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Disease progression | 0 | 1 | 0 | 0 |
| Withdrew: Requirement for alternative therapy | 1 | 2 | 5 | 2 |
| Withdrew: Stem cell transplant | 6 | 6 | 4 | 3 |
| Withdrew: Treatment discontinued | 0 | 2 | 1 | 3 |
| Withdrew: Other | 1 | 0 | 0 | 0 |
Change in platelet nadir from the previous qualifying cycle to the first treatment cycle.
| 10^9/L | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 700 µg | Romiplostim 1000 µg |
|---|---|---|---|---|
| Change in Platelet Nadir | 17.1 ± 8.3 | 11.2 ± 6.1 | 5.1 ± 6.1 | -5.2 ± 7.8 |
Percentage of subjects experiencing grade 3 and/or 4 thrombocytopenia (\<50 x 10\^9/L, and \<25 x 10\^9/L)
| Percentage of participants | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 700 µg | Romiplostim 1000 µg |
|---|---|---|---|---|
| Percentage of Subjects Experiencing Grade 3 or 4 Thrombocytopenia | 62.5 | 81.8 | 80.0 | 88.9 |
Duration of grade 3 and/or 4 thrombocytopenia (\<50 x 10\^9/L and \<25 x 10\^9/L, respectively)
| Day | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 700 µg | Romiplostim 1000 µg |
|---|---|---|---|---|
| Duration of Grade 3 or 4 Thrombocytopenia | 3.9 ± 1.3 | 3.6 ± 0.9 | 6.0 ± 1.5 | 8.3 ± 2.1 |
Percentage of subjects that received platelet transfusions during the first romiplostim treatment cycle
| Percentage of participants | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 700 µg | Romiplostim 1000 µg |
|---|---|---|---|---|
| Percentage of Subjects That Received Platelet Transfusions | 12.5 | 0.0 | 30.0 | 33.3 |
Collected over From the first administration of investigation product through 30 days after the last dose of investigational product or end of the study (including the follow-up period), whichever is longer.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Romiplostim 100 µg | — | 0/8 (0%) | 6/8 (75%) |
| Romiplostim 300 µg | — | 1/11 (9.1%) | 9/11 (81.8%) |
| Romiplostim 700 µg | — | 3/11 (27.3%) | 7/11 (63.6%) |
| Romiplostim 1000 µg | — | 3/9 (33.3%) | 9/9 (100%) |
| Event | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 700 µg | Romiplostim 1000 µg |
|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/8 | 1/11 | 1/11 | 2/9 |
| Abdominal painGastrointestinal disorders | 0/8 | 0/11 | 1/11 | 1/9 |
| Mucosal inflammationGeneral disorders | 0/8 | 0/11 | 0/11 | 1/9 |
| BacteraemiaInfections and infestations | 0/8 | 0/11 | 0/11 | 1/9 |
| Clostridium difficile colitisInfections and infestations | 0/8 | 0/11 | 0/11 | 1/9 |
| Upper respiratory tract infectionInfections and infestations | 0/8 | 0/11 | 0/11 | 1/9 |
| Urinary tract infectionInfections and infestations | 0/8 | 0/11 | 0/11 | 1/9 |
| Renal failure acuteRenal and urinary disorders | 0/8 | 0/11 | 0/11 | 1/9 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/8 | 0/11 | 0/11 | 1/9 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/8 | 0/11 | 1/11 | 0/9 |
| Event | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 700 µg | Romiplostim 1000 µg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/8 | 5/11 | 1/11 | 1/9 |
| FatigueGeneral disorders | 1/8 | 2/11 | 1/11 | 4/9 |
| AnaemiaBlood and lymphatic system disorders | 1/8 | 3/11 | 0/11 | 3/9 |
| NeutropeniaBlood and lymphatic system disorders | 0/8 | 0/11 | 1/11 | 3/9 |
| Oedema peripheralGeneral disorders | 1/8 | 0/11 | 0/11 | 3/9 |
| HypokalaemiaMetabolism and nutrition disorders | 0/8 | 0/11 | 1/11 | 3/9 |
| InsomniaPsychiatric disorders | 2/8 | 0/11 | 0/11 | 0/9 |
| AlopeciaSkin and subcutaneous tissue disorders | 2/8 | 1/11 | 0/11 | 0/9 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/8 | 0/11 | 0/11 | 2/9 |
| PyrexiaGeneral disorders | 0/8 | 1/11 | 0/11 | 2/9 |
| Age Continuous(Year) | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 700 µg | Romiplostim 1000 µg | Total |
|---|---|---|---|---|---|
| Mean | 61.3 ± 6.2 | 58.1 ± 9.5 | 54.0 ± 16.3 | 59.9 ± 10.6 | 58.0 ± 11.5 |
| Sex: Female, Male(Participants) | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 700 µg | Romiplostim 1000 µg | Total |
|---|---|---|---|---|---|
| Female | 3 | 3 | 4 | 5 | 15 |
| Male | 5 | 8 | 7 | 4 | 24 |
| Race/Ethnicity, Customized(Participant) | Romiplostim 100 µg | Romiplostim 300 µg | Romiplostim 700 µg | Romiplostim 1000 µg | Total |
|---|---|---|---|---|---|
| White or Caucasian | 6 | 10 | 10 | 8 | 34 |
| Black or African American | 0 | 0 | 1 | 1 | 2 |
| Hispanic or Latino | 2 | 1 | 0 | 0 | 3 |
No study locations are listed for this record.
The record gives a start of Oct 2005, a primary completion of May 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim